210 related articles for article (PubMed ID: 37636560)
21. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
Bala MM; Celinska-Lowenhoff M; Szot W; Padjas A; Kaczmarczyk M; Swierz MJ; Undas A
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012169. PubMed ID: 33045766
[TBL] [Abstract][Full Text] [Related]
22. Clinical Effects of Dual Antiplatelet Therapy or Aspirin Monotherapy after Acute Minor Ischemic Stroke or Transient Ischemic Attack, a Meta-Analysis.
Condello F; Liccardo G; Ferrante G
Curr Pharm Des; 2021; 27(40):4140-4146. PubMed ID: 34323179
[TBL] [Abstract][Full Text] [Related]
23. Comparison of dual antiplatelet therapies after coronary endarterectomy combined with coronary artery bypass grafting: a cohort study.
Yan H; Tiemuerniyazi X; Song Y; Xu F; Feng W
J Cardiothorac Surg; 2020 Jun; 15(1):155. PubMed ID: 32600365
[TBL] [Abstract][Full Text] [Related]
24. Secondary prevention of antithrombotic therapy in patients with stable cardiovascular disease at high ischemic risk: A network meta-analysis of randomized controlled trials.
Zhu H; Xu X; Wang H; Chen Q; Fang X; Zheng J; Gao B; Tong G; Zhou L; Chen T; Huang J
Front Cardiovasc Med; 2022; 9():1040473. PubMed ID: 36698936
[TBL] [Abstract][Full Text] [Related]
25. Ticagrelor versus clopidogrel in dual antiplatelet therapy after minor stroke or transient ischemic attack: an updated network meta-analysis.
Marinheiro G; Araújo B; Monteiro GA; Leite M; Mutarelli A; Almeida AM; Cavalcante-Neto JF; Rivera A; Pinheiro AC; Telles JPM
J Neurol; 2024 Jun; 271(6):3030-3038. PubMed ID: 38580815
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Dual Antiplatelet Therapies for Minor, Nondisabling, Acute Ischemic Stroke: A Bayesian Network Meta-Analysis.
Lim A; Ma H; Ly J; Singhal S; Pan Y; Wang Y; Johnston SC; Phan TG
JAMA Netw Open; 2024 May; 7(5):e2411735. PubMed ID: 38753327
[TBL] [Abstract][Full Text] [Related]
27. Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point-Blinded, Noninferiority Trial.
Wu H; Xu L; Zhao X; Zhang H; Cheng K; Wang X; Chen M; Li G; Huang J; Lan J; Wei G; Zhang C; Wang Y; Qian J; Ge J;
Circulation; 2023 Jan; 147(3):212-222. PubMed ID: 36335890
[TBL] [Abstract][Full Text] [Related]
28. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
; Bittl JA; Baber U; Bradley SM; Wijeysundera DN
Circulation; 2016 Sep; 134(10):e156-78. PubMed ID: 27026019
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Antiplatelet Therapies in Symptomatic Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis.
De Carlo M; Di Minno G; Sayre T; Fazeli MS; Siliman G; Cimminiello C
Curr Vasc Pharmacol; 2021; 19(5):542-555. PubMed ID: 32819249
[TBL] [Abstract][Full Text] [Related]
30. Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy.
Galli M; Franchi F; Rollini F; Been L; Jaoude PA; Rivas A; Zhou X; Jia S; Maaliki N; Lee CH; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Geisler T; Jennings LK; Bass TA; Angiolillo DJ
Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(7):728-737. PubMed ID: 35353154
[TBL] [Abstract][Full Text] [Related]
31. Antithrombotic treatment in peripheral artery disease.
Olinic DM; Tataru DA; Homorodean C; Spinu M; Olinic M
Vasa; 2018 Feb; 47(2):99-108. PubMed ID: 29160765
[TBL] [Abstract][Full Text] [Related]
32. Comparison of rivaroxaban-based dual antithrombotic and antiplatelet therapies for symptomatic patients with lower-extremity peripheral artery disease post-revascularization: a retrospective cohort study.
Ji Y; Wang B; Wu G; Zhang Y; Wang Q; Zhou M
Ther Adv Chronic Dis; 2023; 14():20406223231213262. PubMed ID: 38085917
[TBL] [Abstract][Full Text] [Related]
33. Antithrombotic Treatments in Patients with Chronic Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomised Controlled Trials.
Bauersachs R; Wu O; Briere JB; Bowrin K; Borkowska K; Jakubowska A; Taieb V; Toumi M; Huelsebeck M
Cardiovasc Ther; 2020; 2020():3057168. PubMed ID: 32695228
[TBL] [Abstract][Full Text] [Related]
34. Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry.
Cesaro A; Gragnano F; Calabrò P; Moscarella E; Santelli F; Fimiani F; Patti G; Cavallari I; Antonucci E; Cirillo P; Pignatelli P; Palareti G; Pelliccia F; Bossone E; Pengo V; Gresele P; Marcucci R;
Int J Cardiol; 2021 Dec; 345():7-13. PubMed ID: 34695525
[TBL] [Abstract][Full Text] [Related]
35. Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic Therapy.
Desai A; Escamilla-Ocanas C; Dilip D; Saber H; Damani R
J Stroke Cerebrovasc Dis; 2021 Apr; 30(4):105654. PubMed ID: 33578352
[TBL] [Abstract][Full Text] [Related]
36. Antithrombotic strategies after transcatheter aortic valve implantation: A systematic review and network meta-analysis of randomized controlled trials.
Ke Y; Wang J; Wang W; Guo S; Dai M; Wu L; Bao Y; Li B; Ju J; Xu H; Jin Y
Int J Cardiol; 2022 Sep; 362():139-146. PubMed ID: 35654173
[TBL] [Abstract][Full Text] [Related]
37. P2Y12 Inhibitors Plus Aspirin Versus Aspirin Alone in Patients With Minor Stroke or High-Risk Transient Ischemic Attack.
Li ZX; Xiong Y; Gu HQ; Fisher M; Xian Y; Johnston SC; Wang YJ
Stroke; 2021 Jul; 52(7):2250-2257. PubMed ID: 34039032
[TBL] [Abstract][Full Text] [Related]
38. Ticagrelor-based antiplatelet regimens in patients treated with coronary artery bypass grafting: a meta-analysis of randomized controlled trials.
von Scheidt M; Bongiovanni D; Tebbe U; Nowak B; Stritzke J; Zhao Q; Zhu Y; Kastrati A; Cassese S; Schunkert H
Eur J Cardiothorac Surg; 2020 Mar; 57(3):520-528. PubMed ID: 31566205
[TBL] [Abstract][Full Text] [Related]
39. Impact of very low dose rivaroxaban in addition to dual antiplatelet therapy on endogenous fibrinolysis in acute coronary syndrome: The VaLiDate-R study.
Gue YX; Memtsas V; Kanji R; Wellsted DM; Busby A; Smith M; Vilar E; Ryding A; Arachchillage DJ; Gorog DA
Thromb Res; 2024 Apr; 236():144-154. PubMed ID: 38447421
[TBL] [Abstract][Full Text] [Related]
40. Aspirin Alone Versus Dual Antiplatelet Therapy after Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis.
Lin X; Wang S; Wang L; Guan Y; Huang J
Cardiovasc Drugs Ther; 2022 Apr; 36(2):271-278. PubMed ID: 33570686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
